A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Active:	Yes
Cancer Type:	Head and Neck Cancer	NCT ID:	NCT06457503
Trial Phases:	Phase IV	Protocol IDs:	CHS-007-01/RTOG 3521 (primary) NCI-2024-05550
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Coherus Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06457503

Summary

This study aims to investigate toripalimab with chemotherapy in participants with
nasopharyngeal cancer.

Objectives

The primary objective of this study is to evaluate the efficacy of toripalimab in
combination with chemotherapy (cisplatin and gemcitabine), as measured by objective
response rate (ORR) assessed by a Blinded Independent Central Review Committee (BICR)
according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in first-line
recurrent metastatic nasopharyngeal cancer participants (both Epstein-Barr virus (EBV)
and non-EBV-associated).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.